Literature DB >> 24006295

Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.

Eduardo Gotuzzo1, Sergio Yactayo, Erika Córdova.   

Abstract

Abstract. Current regulations stipulate a yellow fever (YF) booster every 10 years. We conducted a systematic review of the protective efficacy and duration of immunity of YF vaccine in residents of disease-endemic areas and in travelers to assess the need for a booster in these two settings and in selected populations (human immunodeficiency virus-infected persons, infants, children, pregnant women, and severely malnourished persons). Thirty-six studies and 22 reports were included. We identified 12 studies of immunogenicity, 8 of duration of immunity, 8 of vaccine response in infants and children, 7 of human-immunodeficiency virus-infected persons, 2 of pregnant women, and 1 of severely malnourished children. Based on currently available data, a single dose of YF vaccine is highly immunogenic and confers sustained life-long protective immunity against YF. Therefore, a booster dose of YF vaccine is not needed. Special considerations for selected populations are detailed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24006295      PMCID: PMC3771278          DOI: 10.4269/ajtmh.13-0264

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  77 in total

1.  Yellow fever, 1998-1999.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2000-10-06

2.  Yellow fever as an endemic/epidemic disease and priorities for vaccination.

Authors:  T P Monath
Journal:  Bull Soc Pathol Exot       Date:  2006-12

3.  Jungle yellow fever in the central Amazon.

Authors:  M L Barros; G Boecken
Journal:  Lancet       Date:  1996-10-05       Impact factor: 79.321

4.  Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients.

Authors:  Jérôme Pacanowski; Karine Lacombe; Pauline Campa; Magdalena Dabrowska; Jean-Dominique Poveda; Jean-Luc Meynard; Jean-Louis Poirot; Laurent Fonquernie; Pierre-Marie Girard
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-01       Impact factor: 3.731

Review 5.  Yellow fever: an update.

Authors:  T P Monath
Journal:  Lancet Infect Dis       Date:  2001-08       Impact factor: 25.071

6.  Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection.

Authors:  Kitisak Kengsakul; Kriengkrai Sathirapongsasuti; Sompone Punyagupta
Journal:  J Med Assoc Thai       Date:  2002-01

7.  Yellow fever in the Gambia, 1978--1979: epidemiologic aspects with observations on the occurrence of orungo virus infections.

Authors:  T P Monath; R B Craven; A Adjukiewicz; M Germain; D B Francy; L Ferrara; E M Samba; H N'Jie; K Cham; S A Fitzgerald; P H Crippen; D I Simpson; E T Bowen; A Fabiyi; J J Salaun
Journal:  Am J Trop Med Hyg       Date:  1980-09       Impact factor: 2.345

8.  H1N1 2009 influenza virus infection during pregnancy in the USA.

Authors:  Denise J Jamieson; Margaret A Honein; Sonja A Rasmussen; Jennifer L Williams; David L Swerdlow; Matthew S Biggerstaff; Stephen Lindstrom; Janice K Louie; Cara M Christ; Susan R Bohm; Vincent P Fonseca; Kathleen A Ritger; Daniel J Kuhles; Paula Eggers; Hollianne Bruce; Heidi A Davidson; Emily Lutterloh; Meghan L Harris; Colleen Burke; Noelle Cocoros; Lyn Finelli; Kitty F MacFarlane; Bo Shu; Sonja J Olsen
Journal:  Lancet       Date:  2009-07-28       Impact factor: 79.321

Review 9.  [Antiviral immunization of immunocompromised adults, literature review].

Authors:  P Duchet Niedziolka; O Launay; D Salmon Ceron; P-H Consigny; T Ancelle; D Van der Vliet; O Lortholary; T Hanslik
Journal:  Rev Med Interne       Date:  2007-09-21       Impact factor: 0.728

10.  [Yellow fever virus 17D neutralising antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue].

Authors:  Sergio Y Gómez; Raquel E Ocazionez
Journal:  Rev Salud Publica (Bogota)       Date:  2008 Nov-Dec
View more
  72 in total

1.  Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.

Authors:  Angela Huttner; Selidji Todagbe Agnandji; Christophe Combescure; José F Fernandes; Emmanuel Bache Bache; Lumeka Kabwende; Francis Maina Ndungu; Jessica Brosnahan; Thomas P Monath; Barbara Lemaître; Stéphane Grillet; Miriam Botto; Olivier Engler; Jasmine Portmann; Denise Siegrist; Philip Bejon; Peter Silvera; Peter Kremsner; Claire-Anne Siegrist
Journal:  Lancet Infect Dis       Date:  2018-04-05       Impact factor: 25.071

Review 2.  Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection.

Authors:  J Erin Staples; Alan D T Barrett; Annelies Wilder-Smith; Joachim Hombach
Journal:  NPJ Vaccines       Date:  2020-07-06       Impact factor: 7.344

3.  Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.

Authors:  Wen-Yang Tsai; Anna Durbin; Jih-Jin Tsai; Szu-Chia Hsieh; Stephen Whitehead; Wei-Kung Wang
Journal:  J Virol       Date:  2015-07       Impact factor: 5.103

4.  Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice.

Authors:  Irina Tretyakova; Brian Nickols; Rachmat Hidajat; Jenny Jokinen; Igor S Lukashevich; Peter Pushko
Journal:  Virology       Date:  2014-08-16       Impact factor: 3.616

5.  Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.

Authors:  Enoch Muyanja; Aloysius Ssemaganda; Pearline Ngauv; Rafael Cubas; Helene Perrin; Divya Srinivasan; Glenda Canderan; Benton Lawson; Jakub Kopycinski; Amanda S Graham; Dawne K Rowe; Michaela J Smith; Sharon Isern; Scott Michael; Guido Silvestri; Thomas H Vanderford; Erika Castro; Giuseppe Pantaleo; Joel Singer; Jill Gillmour; Noah Kiwanuka; Annet Nanvubya; Claudia Schmidt; Josephine Birungi; Josephine Cox; Elias K Haddad; Pontiano Kaleebu; Patricia Fast; Rafick-Pierre Sekaly; Lydie Trautmann; Denis Gaucher
Journal:  J Clin Invest       Date:  2014-06-09       Impact factor: 14.808

Review 6.  Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day.

Authors:  Natalie D Collins; Alan D T Barrett
Journal:  Curr Infect Dis Rep       Date:  2017-03       Impact factor: 3.725

Review 7.  Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine.

Authors:  Huabin Liang; Min Lee; Xia Jin
Journal:  Cell Mol Immunol       Date:  2015-10-05       Impact factor: 11.530

Review 8.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

Review 9.  Vaccination strategies against Zika virus.

Authors:  Estefania Fernandez; Michael S Diamond
Journal:  Curr Opin Virol       Date:  2017-04-19       Impact factor: 7.090

10.  Inadvertent yellow fever vaccination of a patient with Crohn's disease treated with infliximab and methotrexate.

Authors:  Christina Ekenberg; Nina Friis-Møller; Thomas Ulstrup; Claus Aalykke
Journal:  BMJ Case Rep       Date:  2016-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.